SPX3,825.33+39.95 1.06%
DIA310.85+3.03 0.98%
IXIC11,127.85+99.11 0.90%

BRIEF-Imago Biosciences Presents Positive Data From Ongoing Phase 2 Study Of Bomedemstat

reuters.com · 06/10/2022 03:06
BRIEF-Imago Biosciences Presents Positive Data From Ongoing Phase 2 Study Of Bomedemstat

- Imago BioSciences Inc IMGO:

  • IMAGO BIOSCIENCES PRESENTS POSITIVE DATA FROM ONGOING PHASE 2 STUDY OF BOMEDEMSTAT IN ESSENTIAL THROMBOCYTHEMIA AT EHA 2022

  • IMAGO BIOSCIENCES-AS OF 29 APRIL BOMEDEMSTAT SHOWED DURABILITY OF RESPONSE WITH 81% PATIENTS ACHIEVING NORMALIZED PLATELET COUNT FOR AT LEAST12 WEEKS

Source text for Eikon: ID:nGNX17ghQl

Further company coverage: IMGO


((Reuters.Briefs@thomsonreuters.com;))